UCB Japan
UCB Japan is a subsidiary of the global biopharmaceutical company UCB, headquartered in Brussels, Belgium. The company focuses on research, development, and provision of innovative medicines in the fields of neurology and immunology/inflammation, aiming to improve the lives of patients with serious diseases. Established in 1988, UCB Japan markets several key products including Keppra®, Bimzelx®, and others, and is committed to creating value for patients and contributing to healthcare and wellness in Japan. The company is actively involved in clinical trials for various diseases, including psoriasis, systemic lupus erythematosus, and epilepsy, among others, and emphasizes innovation, sustainability, and social responsibility.
Industries
Nr. of Employees
large (251-1000)
UCB Japan
8-17-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
Products
イーケプラ (antiepileptic medicine)
Prescription therapeutic indicated for epilepsy.
ビムパット (antiepileptic medicine)
Prescription therapeutic indicated for epilepsy.
シムジア (rheumatology/dermatology biologic)
Therapeutic biologic indicated for inflammatory conditions such as rheumatoid arthritis and psoriasis.
ビンゼレックス (psoriasis medicine)
Prescription therapeutic for psoriasis; available in a subcutaneous autoinjector formulation.
リスティーゴ (product listed)
Listed as a marketed product in the company summary (specific indications not detailed in extracted pages).
ジルビスク (product listed)
Listed as a marketed product in the company summary (specific indications not detailed in extracted pages).
イーケプラ (antiepileptic medicine)
Prescription therapeutic indicated for epilepsy.
ビムパット (antiepileptic medicine)
Prescription therapeutic indicated for epilepsy.
シムジア (rheumatology/dermatology biologic)
Therapeutic biologic indicated for inflammatory conditions such as rheumatoid arthritis and psoriasis.
ビンゼレックス (psoriasis medicine)
Prescription therapeutic for psoriasis; available in a subcutaneous autoinjector formulation.
リスティーゴ (product listed)
Listed as a marketed product in the company summary (specific indications not detailed in extracted pages).
ジルビスク (product listed)
Listed as a marketed product in the company summary (specific indications not detailed in extracted pages).
Services
Competitive funding program for academic societies to support public calls for research addressing serious diseases; application-based selection.
Telephone and online inquiry handling and web portals for patients and healthcare professionals, including medical information, complaint intake and integrity reporting channels.
Operational support for interventional and observational clinical studies including registry disclosure and linkage to the national clinical research registry (jRCT).
Competitive funding program for academic societies to support public calls for research addressing serious diseases; application-based selection.
Telephone and online inquiry handling and web portals for patients and healthcare professionals, including medical information, complaint intake and integrity reporting channels.
Operational support for interventional and observational clinical studies including registry disclosure and linkage to the national clinical research registry (jRCT).
Expertise Areas
- Clinical trial management and operations
- Observational and real‑world evidence studies
- Neurology therapeutics (epilepsy and neuromuscular disorders)
- Immunology and inflammation therapeutics (including rheumatology and dermatology)
Key Technologies
- Interventional clinical trial operations and jRCT registry linkage
- Prospective observational study methodology
- Post‑marketing safety surveillance systems
- GMP pharmaceutical manufacturing
News & Updates
2024/8/23 - Announcement of Grant Program for Research on Difficult Diseases
UCB Japan established the UCBJ Science Promotion Fund to support research programs that contribute to the lives of people living with intractable diseases.
2023/9/27 - Renewal of Corporate Website
The corporate website of UCB Japan was renewed to better serve patients, healthcare professionals, and stakeholders.
2025/06/26 - Clinical Study on Bimekizumab for Psoriasis in Japan
A prospective observational study called 'SAKURA' was initiated to evaluate quality of life and treatment satisfaction in adult patients with moderate to severe psoriasis treated with Bimekizumab.
2025/06/25 - Presentation of Phase III Data on Dapirolizumab Pegol for SLE at EULAR
UCB announced the presentation of Phase III trial data for Dapirolizumab Pegol in treating systemic lupus erythematosus (SLE) at the European League Against Rheumatism (EULAR) conference.
2025/05/29 - Launch of Binzereksu® 320mg Auto-Injector
UCB Japan announced the launch of Binzereksu® 320mg auto-injector for patient convenience.
UCB Japan’s Commitment to Patients
UCB Japan is dedicated to transforming patients' lives through innovative therapies and supporting healthcare professionals.
2024/8/23 - Announcement of Grant Program for Research on Difficult Diseases
UCB Japan established the UCBJ Science Promotion Fund to support research programs that contribute to the lives of people living with intractable diseases.
2023/9/27 - Renewal of Corporate Website
The corporate website of UCB Japan was renewed to better serve patients, healthcare professionals, and stakeholders.
2025/06/26 - Clinical Study on Bimekizumab for Psoriasis in Japan
A prospective observational study called 'SAKURA' was initiated to evaluate quality of life and treatment satisfaction in adult patients with moderate to severe psoriasis treated with Bimekizumab.
2025/06/25 - Presentation of Phase III Data on Dapirolizumab Pegol for SLE at EULAR
UCB announced the presentation of Phase III trial data for Dapirolizumab Pegol in treating systemic lupus erythematosus (SLE) at the European League Against Rheumatism (EULAR) conference.
2025/05/29 - Launch of Binzereksu® 320mg Auto-Injector
UCB Japan announced the launch of Binzereksu® 320mg auto-injector for patient convenience.
UCB Japan’s Commitment to Patients
UCB Japan is dedicated to transforming patients' lives through innovative therapies and supporting healthcare professionals.